Table 3

Randomised controlled trials of baricitinib in RA

Embedded Image
  • *The primary objective evaluated non-inferiority of bari 4 mg monotherapy to MTX on ACR20.

  • ‡38% of the patients had a history of treatment with at least one biologic DMARD that was not a TNF inhibitor.

  • ACR, American College of Rheumatology; ADA, adalimumab; bDMARD, biological DMARD; csDMARD, conventional synthetic DMARD; DMARD, disease-modifying antirheumatic drug; IR, inadequate responder; MTX, methotrexate; PROs, patient-reported outcomes; RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor.